8:30 PM: Radio Interview with Dr. D'Olimpio
"Dr. James D'Olimpio, of the North Shore Hospital, a
member of Advanced Viral Research Corporation's Scientific
Advisory Board, who serves also as the company's spokesperson,
will be talking about the company and its lead drug product
AVR118 in a radio interview. The broadcast will be on a
show called Community Issues by WHPC Radio, 90.3FM in Long
Island. The interview will air on Monday, December 22 at 8:30
PM, on Tuesday, December 23 at 7AM and on Wednesday, December
24 at 5:30 AM and 2:30 PM."
here it is, conversation with the doc was about pallative
care and pain reduction for people with cancer and aids,
conversation lasted 30 minutes with the last ten minutes
discussing avr118, the doc is really excited about the
results he has seen with the israel trials in wasting
cachexia, he claims avr118 is having good results, he is
working very hard with advr and other top docs involved to
get thru the israeli trials and get the info needed for the
fda. yes they mentioned advr and yonkers and trials in
israel, seems he is very excited about the future of advr. - - - - - View
Dr. James D'Olimpio expressed himself in a casual but articulate
manner. He is triple board certified and is associated with the
Palliative care at North Shore University Hospital. He only spent
about five minutes discussing the drug and the company. He was
involved in the development of the studies in Israel and is helping
to develop more studies for our FDA. He specifically said he would
be careful not to tout an unproven drug such as AVR118 but was very
interested in helping the drug be properly tested. The results he
has seen have impressed him. He seems very interested in the future
of this drug.
This looks like a great man to have helping ADVR.
Good luck to all!!!
(Voluntary Disclosure: Position- Long)
it was a great interview! Kudos to Dr. James D'Olimpio!
It was so nice to hear the voice behind the name.
Yes, the discussion was on pallative care and relieving the
suffering of the patient. He discussed Dr. Kvorkian and assisted
suicide which he doesn't agree with. He said it's the intent of a
physician to relieve the suffering of a patient and not by killing
the patient intentionally as Dr. Kvorkian did. To identify and
refine it correctly you can't relieve suffering by active
After the intermission ADVR and AVR118 was discussed. I was very
impressed with his presentation on body wasting,
trying to reverse weight loss and improve the quality of life. He
said this is a very powerful technology platform and is very
impressed with the information coming out of the AVR118 clinical
trials in Israel which we'll modify and model it to get through the
He said that the AVR118 platform makes the patient feel better
without making them feel sick first and to date has shown no
indication of human toxicity and is an immunomodulator, etc., etc.,
All in all, a very impressive interview.
Dr. Olimpio is an example of the quality people working
with ADVR, we have reason to be optimistic. He appeared to
be extremely well educated, very experienced and highly
articulate. His background appears custom made for the work
he is doing with ADVR 118, which he discussed at length during the
interview. He was in no way hyping the drug, but
clearly stated that he was very interested in ADVR 118 because of
its unique and promising characteristics. He talked about the trials
in Isreal and how those trials
would be remodeled to allow the clinical trials in the US
to go forward. He talked about the great value to cancer
and aids patients to provide treatment to prevent the wasting effect
that occurs while these patients are being
treated for other aspects of the disease. There were many
interesting and important topics covered in this half hour interview
which was broadcast from Nassau Community College
FM radio. This college is located in Nassau County, New York and you
might want to contact them for a transcript
of the interview. If I can get one, I'll post it. This interview was
a real treat for the holidays. Merry Christmas and Happy Chanukah!
and a Prosperous New Year!
(Voluntary Disclosure: Position- Long;
ST Rating- Buy; LT Rating- Buy)